Tubulis GmbH is the latest biotech to benefit from big pharma's surge of interest in next-generation antibody-drug conjugates (ADCs), inking a deal that could be worth over $1bn.
The German firm has inked a license agreement with Bristol Myers Squibb Company that gives the latter exclusive rights to Tubulis’ Tubutecan payloads in combination with its proprietary P5...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?